MRAS, SHOC2, PP1C and YAP1 mRNA level variations at 72 hours of targeted therapy in KRAS G12C-mutant non-small cell lung cancer cell lines
Background The treatment of KRAS G12C-mutant non-small cell lung cancer (NSCLC) has become a dominant field of ongoing translational research. Still, the effect of the first KRAS G12C inhibitor, sotorasib, or next-generation inhibitors, such as fulzerasib, in KRAS-mutant NSCLC patients is short-lived. Although the obje...